7.2 Weak D, Partial D, and Rh Antibodies

7.2 Weak D, Partial D, and Rh Antibodies

Quick Answer: Weak D is quantitative — fewer D sites, all epitopes intact — and usually types as D+ only by IAT. Molecular types 1, 2, and 3 can receive D+ red cells and are not at risk for alloanti-D. Partial D is qualitative epitope loss; those patients can make anti-D and must be managed as D-neg. U.S. serologic weak D testing is required on donors and on newborns of D-neg mothers; patients were historically issued D-neg units if weak D, but CAP/AABB recommend RHD genotyping so types 1/2/3 do not consume D-neg inventory. Anti-D is IgG, 37 °C / AHG, clinically significant (HDFN and delayed / extravascular HTR), and not naturally occurring. Enzymes enhance Rh. D does not show classic dosage the way Kidd, Duffy, and Rh C/c/E/e do.

II.B.3 on the June 9, 2026 outline is not finished when you can recite R1r. The exam’s money distinction is weak versus partial D, because the two categories write opposite transfusion and RhIG orders.

Weak D is a numbers problem

Weak D means the D protein is complete but poorly expressed. Most causative substitutions sit in transmembrane or intracellular loops and interfere with insertion, not with an extracellular epitope. Antigen-site counts fall from the usual 10,000–30,000 into the hundreds or low thousands. Immediate-spin monoclonal anti-D is negative or ≤1+; the weak D test (anti-D carried through wash and AHG) becomes positive. A valid weak D test needs a negative control at AHG. If the control is positive, the IAT D type is unreadable.

Types 1, 2, and 3 account for the large majority of serologic weak D in people of European ancestry. High-quality evidence shows they do not make alloanti-D. Once the genotype is known they may be transfused with D+ red cells and, if pregnant, they do not need RhIG. That single reclassification is why molecular typing conserves D-neg units. Other numbered weak D types, including some type 4 variants, still lack that same safety file and are managed as D-neg in most U.S. policies.

Del is weaker still — often fewer than 50 sites — and is missed by IAT. You find it only by adsorbing anti-D and eluting it back off the cells. Del is enriched among serologic D-neg people of East Asian ancestry (classically RHD1227A). A Del unit labeled D-neg can immunize a true D-neg recipient. That is the rare “no history” anti-D the outline is nodding at: not naturally occurring, just an invisible D exposure.

Ceppellini weakening (C in trans to RHD, Section 7.1) can look like weak D at the bench. The genotype is ordinary RHD; the haplotype geometry is not a partial D.

Partial D is a missing-epitope problem

Partial D means at least one extracellular D epitope is gone, usually because a stretch of RHD was replaced by RHCE (RHD-CE-D hybrid). Site number may be normal or reduced, so the tube can read strong D+ or weak D. The clinical rule does not care about strength. The person can see the missing epitope on a normal D+ cell as foreign and make alloanti-D.

DVI is the European teaching partial D. Many patient-typing monoclonal IgM clones miss DVI, so the patient types D-neg and is issued D-neg red cells and RhIG — that is intentional protection. Donor-typing reagents are required to detect DVI, so the same person as a donor is labeled D+ and will not be transfused into a D-neg recipient. DIIIa, DAR, DAU, and other hybrids are enriched in African ancestry and matter in sickle-cell programs; a serologic e+ or D+ may still be a partial antigen that can make the corresponding alloantibody.

Serology cannot finish this table. A 2+ IAT D does not tell you type 1 from DVI. RHD genotyping does.

What U.S. practice actually requires

Keep the three populations separate. They do not share one weak-D rule.

Allogeneic donors. AABB Standards require a serologic weak D test whenever the immediate-spin D is negative. Any donor who is weak D+ is labeled Rh-positive. A weak D unit in a D-neg recipient is an immunizing event.

Newborns of D-neg mothers. Weak D testing of the infant is required. A weak D+ neonate counts as D+ for maternal RhIG. Missing that test is how a D-neg mother leaves the hospital unprotected.

Patients (recipients). Weak D testing is not required. Historically, a serologic weak D patient was issued D-neg red cells “to be safe,” because the tube cannot exclude partial D. That policy protects partial D and wastes D-neg inventory on types 1, 2, and 3. The 2015 CAP/AABB (with ACOG, ABC, and ARC) joint statement recommends RHD genotyping for patients — especially women of childbearing potential — who have a serologic weak D, then managing confirmed types 1, 2, and 3 as D-positive. Until the genotype returns, issue D-neg units and, if pregnant, give RhIG.

Do not apply the donor rule to the patient, and do not skip the neonatal weak D test because “we do not weak-D adults.”

Anti-D and the other Rh antibodies

Anti-D is immune, not naturally occurring. It appears after transfusion, pregnancy, or a cryptic Del / weak-D donor exposure. It is IgG (mostly IgG1 and IgG3), reacts at 37 °C and in the AHG phase, and is clinically significant. It causes HDFN (the historic reason RhoGAM exists) and hemolytic transfusion reactions that are typically delayed and extravascular — fever, falling hemoglobin, spherocytes, positive DAT — not ABO-style intravascular blow-up. Complement binding is inconsistent; do not wait for hemolysis in the tube to call anti-D dangerous.

There is no routine naturally occurring anti-D. A D-neg adult with anti-D and “no history” still had an exposure you have not found, received IVIG or RhIG, or was immunized by a unit that typed D-neg and was Del. Do not file anti-D next to anti-A, anti-Le(a), or anti-M as a cold naturally occurring antibody.

The other common Rh antibodies — anti-C, -c, -E, -e, -f, -Ce, -G — are also usually IgG, AHG, and clinically significant. Anti-E can have an IgM room-temperature component; do not dismiss a 37 °C anti-E because it also reacted at immediate spin. Anti-e in a seemingly e+ patient is a partial e problem, especially in sickle-cell care, not an autoantibody by default.

Enzymes (ficin, papain, bromelin) enhance Rh. A panel that gets stronger after ficin is consistent with Rh, Kidd, Lewis, I, and P1 and argues against Duffy and most MNS. Enhancement is a tool, not a diagnosis.

Dosage: D is the exception inside Rh

C, c, E, and e show dosage: stronger with double-dose (R2R2 for E, rr for c and e) than with single-dose cells. Kidd is the textbook dosage system; Duffy often shows it too. D usually does not show that classic homozygous-versus-heterozygous pattern on a panel. D site number tracks haplotype more than zygosity: R2R2 cells carry more D than R1R1, and R1r carries less than either — but you do not ID anti-D by watching it fail a single-dose D+ cell. If a stem asks which Rh antibody is least likely to show dosage, the answer is anti-D.

Immunogenicity still ranks D first among protein antigens, then K, then c and E, then C and e. That is why a missed D+ unit is a bigger event than a missed C+ unit, and why RhIG exists for D and not for E.

Exam traps

• Treating every IAT-only D as partial D, or every strong D as “cannot make anti-D.”
• Issuing D-neg units forever to a genotyped type 1, 2, or 3 weak D.
• Skipping donor or newborn weak D testing because patient testing is optional.
• Labeling a DVI donor as D-neg. Donor reagents must catch DVI.
• Calling anti-D naturally occurring.
• Using dosage to rule anti-D in or out the way you rule anti-Jk(a).
• Calling Ceppellini weakening a hybrid partial D.